Evolving Market Access Strategies – Pricing and Reimbursement Landscape in Major Developed Pharmaceutical Markets
As the overall costs of drugs continue to increase and pricing pressures shift the dynamics of the healthcare market, pharmaceutical companies must analyze real-world trends in different treatment spaces, and assess existing and expected levels of competition, in order to gain optimal market access. This kind of analysis, known as Health Economics and Outcome Research (HEOR) is an important element of market access which encompasses aspects such as real-world data, quality of life, budget impact, and cost-effectiveness, along with clinical efficiency. Traditionally, once a drug was registered in a country, it was automatically reimbursed and available for an eligible population of patients. Today, however, regulatory approval does not guarantee market access, as the cost-effectiveness of any given drug must be thoroughly demonstrated before it receives coverage in a health system. HEOR offers some solutions to this aspect of drug development and marketing, as it helps to collect the evidence that demonstrates the impact of new therapies on healthcare budgets, which in turn will help to price products optimally.
CBR Pharma’s latest report Evolving Market Access Strategies – Pricing and Reimbursement Landscape in Major Developed Pharmaceutical Markets provides analysis of the key elements of pharmaceutical market access, such as Health Economics and Outcome Research (HEOR) and Health Technology Assessment (HTA), as well as pricing and reimbursement strategies for pharmaceutical products. It includes information on market policies in the US, Canada, France, Germany, Italy, Spain, the UK, and Japan, along with a number of relevant case studies.
Published: Jan’16 – Single user price: $2,995